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ABSTRACT
Aims This paper provides a concise review of the efﬁcacy, effectiveness and affordability of health-care interventions to
promote and assist tobacco cessation, in order to inform national guideline development and assist countries in planning
their provision of tobacco cessation support.Methods Cochrane reviews of randomized controlled trials (RCTs) of major
health-care tobacco cessation interventions were used to derive efﬁcacy estimates in terms of percentage-point increases
relative to comparison conditions in 6–12-month continuous abstinence rates. This was combined with analysis and
evidence from ‘real world’ studies to form a judgement on the probable effectiveness of each intervention in different
settings. The affordability of each intervention was assessed for exemplar countries in each World Bank income category
(low, lower middle, upper middle, high). Based onWorld Health Organization (WHO) criteria, an intervention was judged
as affordable for a given income category if the estimated extra cost of saving a life-year was less than or equal to the
per-capita gross domestic product for that category of country. Results Brief advice from a health-care worker given
opportunistically to smokers attending health-care services can promote smoking cessation, and is affordable for countries
in all World Bank income categories (i.e. globally). Proactive telephone support, automated text messaging programmes
and printed self-help materials can assist smokers wanting help with a quit attempt and are affordable globally.
Multi-session, face-to-face behavioural support can increase quit success for cigarettes and smokeless tobacco and is afford-
able in middle- and high-income countries. Nicotine replacement therapy, bupropion, nortriptyline, varenicline and
cytisine can all aid quitting smoking when given with at least some behavioural support; of these, cytisine and nortripty-
line are affordable globally. Conclusions Brief advice from a health-care worker, telephone helplines, automated text
messaging, printed self-help materials, cytisine and nortriptyline are globally affordable health-care interventions to
promote and assist smoking cessation. Evidence on smokeless tobacco cessation suggests that face-to-face behavioural
support and varenicline can promote cessation.
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INTRODUCTION
Stopping smoking improves life expectancy and reduces
the risk of chronic disease. The earlier the age of stopping,
the greater the beneﬁt; studies in the United Kingdom and
United States estimate that stopping in young adulthood
recovers an average of 10years of life [1,2]. The health
risks from other forms of tobacco use are mostly lower (in
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the case of Swedish-type snus, much lower) than from
smoking, but reducing prevalence of tobacco use in general
is an important public health goal [3]. Interventions that
promote and assist smoking cessation are among the most
cost-effective life-preserving interventions available in
high-income countries; interventions that can help as few
as 1% of smokers to stop for at least 6months can be highly
cost-effective ways of saving lives [4]. Interventions to
promote and assist smoking cessation include mass media
campaigns, advertising bans, ﬁscal measures and
legislation to ban smoking in indoor public areas [5], as
well as ‘health-care interventions’, i.e. interventions
typically delivered or made available to individuals through
a country’s health-care system [6].
Health-care interventions to promote and support
smoking cessation have a strong evidence base and are
available in many countries. These interventions include
brief advice and behavioural support from health-care
workers and a range of medications, including nicotine
replacement therapy (NRT), varenicline, bupropion,
nortriptyline and cytisine [7–10]. These interventions
may be paid for directly by individual smokers, health
insurance companies or the state. There is far less research
on interventions to support cessation from other forms of
tobacco use, but such evidence does exist.
The World Health Organization (WHO) Framework
Convention on Tobacco Control (FCTC) [11] is a UN health
treaty that sets out a range of measures that countries
should take to reduce tobacco use. By October 2014 there
were 179 Parties to the Treaty, making it one of the most
widely adopted of all UN treaties. Article 14 of the Treaty
obliges Parties to the treaty to ‘develop and disseminate…
guidelines based on scientiﬁc evidence… and take effective
measures to promote cessation… and treatment of tobacco
dependence’. In November 2010 the fourth Conference of
the Parties to the treaty adopted guidelines for the
implementation of Article 14, which set out in more detail
the steps Parties should take to develop tobacco cessation
support systems [12]. These guidelines recommend that
Parties strengthen or create sustainable infrastructure to
motivate quit attempts and ensure wide access to cessation
support. However, a recent global survey shows that in
many countries relatively little progress has been made
on this [13].
This paper aims to assist the process of implementing
Article 14 of the FCTC by assessing the efﬁcacy,
effectiveness and affordability of the major health-care
interventions to promote and assist tobacco cessation, in
most cases relating to smoking [14]. It provides a concise
summary of the evidence which, with an accompanying
affordability calculator spreadsheet, can be used in
guideline development, and in selecting cessation interven-
tions appropriate to a country’s current situation and
resources. Countries would otherwise need to undertake
such a review themselves, a process that can be
time-consuming and costly, especially for low- and
middle-income countries [15].
We use Cochrane reviews of tobacco cessation
interventions to obtain efﬁcacy estimates in terms of the
percentage of tobacco users in randomized controlled trials
(RCTs) helped to stop using those interventions. We then
review additional studies that may help to form a
judgement about the real-world effectiveness of the inter-
ventions, and contextual and implementation factors that
may enhance or reduce this effectiveness. Then we
estimate the incremental cost-effectiveness ratios (ICERs)
for the effective interventions for countries in different
World Bank income categories. ICERs give the incremental
cost incurred for an incremental health outcome, usually
expressed as cost per life-year gained or cost per
quality-adjusted life-year gained. Because ICERs are the
ratio of the change in costs to incremental beneﬁts of an
intervention, they are good measures to compare different
interventions used in tobacco cessation and across coun-
tries. These ICERs can then be used to assess the
affordability of the interventions globally taking account
of income levels in relevant countries.
The paper and the affordability calculator have under-
gone extensive review, user testing and revision prior to
submission as a published paper, with an advisory group
of key stakeholders in low- and middle-income countries,
to help ensure that they meet their needs. The members
of the advisory panel are listed in Box 1.
Box 1. International advisory panel
Lekan Ayo-Yusuf, Director/Dean, Sefako Makgatho
Health Sciences University, Medunsa, South Africa;
Beatriz Champagne, Executive Director, InterAmerican
Heart Foundation, Buenos Aires, Argentina; Elma
Correa-Acevedo, Pneumologist and Tobacco Clinic
Coordinator, Instituto Nacional de Cancerología,
México City, México; Thomas Glynn, Consulting
Professor, Stanford Prevention Research Center, School
of Medicine, Stanford University; USA; Feras Hawari,
Director, Cancer Control Ofﬁce and Chief, Section of
Pulmonary and Critical Care, King Hussein Cancer
Centre, Amman, Jordan; Hom Lal Shresha, Honorary
Research Fellow, Non-Smokers’ Rights Association of
Nepal, Kathmandu, Nepal; Vimla Moodley, Director,
Health Promotion, National Department of Health,
South Africa; Caleb Otto, Ambassador and Permanent
Representative of Palau to the United Nations, USA;
Dennis Rada, Tobacco Control Coordinator, Inter-
American Heart Foundation, La Paz, Bolivia; Javier
Saimovici, Chief of Home Care Section, Internal
Medicine Department and Tobacco Control Program
Member, Italian Hospital of Buenos Aires, Argentina;
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Oleg Salagay, Deputy Director, Department of
International Cooperation and Public Relations,
Ministry of Health of the Russian Federation, Moscow,
Russia; Dan Xiao, Tobacco Medicine and Smoking
Cessation Center in China-Japan Friendship Hospital,
Beijing, China
Considering ‘efﬁcacy’ (the effect of an intervention in test
conditions compared with a speciﬁed alternative) in more
detail, Cochrane reviews provide rigorous, independent,
quantitative estimates and are subject to a consistent
quality control process. They provide meta-analyses of
RCTs usually with a minimum of 6-month follow-up,
synthesizing data from direct head-to-head comparisons
between interventions and comparison conditions. It is
important to recognize that efﬁcacy estimates based on
the Cochrane reviews depend upon the particular
circumstances of the trials conducted, including the
control conditions used and the target population.
However, they provide the best estimates available and a
starting point for consideration of effectiveness.
There are many reasons why efﬁcacy estimates from
RCTs might not translate into the same level of
effectiveness in practice [16], particularly when
considering delivery in very different cultures and
health-care systems. We believe, therefore, that it is
important to conduct an analysis of likely transferability
to different contexts and to supplement efﬁcacy estimates
with evidence from ‘real-world’ studies, which match as
closely as possible the context in which the intervention
would be delivered. Real-world studies often have to be
‘observational’ (involving cohort studies, analysis of
clinical records or surveys), rather than experimental. This
is, in part, because willingness to be randomized to
conditions in smoking cessation is amajor source of sample
bias. By themselves they cannot deﬁnitely establish a
causal connection between interventions and outcomes.
However, they can help to form a judgement about
whether or not effect sizes found in RCTs are likely to
translate into practice in the settings of interest.
An intervention may be effective but not affordable in
many countries, particularly low- and middle-income
countries. This paper therefore uses the efﬁcacy esti-
mates, qualiﬁed if necessary by real-world effectiveness
evidence, to make affordability judgements. Affordability
of treatments can be construed in a variety of ways
[17], depending on whether the individual or the state
is paying directly, and whether the treatment has to be
used over a long period or can be used for a short
duration.
We deﬁne as affordable for a given country an
intervention for which the ICER was less than the per
capita gross domestic product (GDP). This corresponds to
the WHO deﬁnition of ‘highly cost effective’ [18]. It is
important to recognize that the ICERs for a given country
rely upon estimates of background quit rates and other
causes of mortality, as well as effectiveness of interventions,
if they were to be delivered in that country. The
background quit rates are mostly not known, and so we
have to use data from countries where they are known
and apply appropriate caveats to any conclusions drawn.
In recognition of all these factors, we provide a model
(available as a spreadsheet, with instructions, accompany-
ing this paper) with which users can vary the parameters
used for a given country to assess affordability across a
range of user-deﬁned assumptions.
An important issue with regard to any tobacco cessa-
tion intervention is the question about how far it aims to
promote attempts to quit versus helping quit attempts to
succeed. This leads to what may be termed ‘the ﬁrst law
of tobacco cessation’, stated as:
E ¼ N  S
where E is the number of ex-tobacco users generated in a
given period, N is the number of tobacco users attempting
to stop and S is the probability of success of those quit
attempts. Note that one may adopt different time-periods
for someone counting as an ex-user, but for present
purposes only permanent ex-users are considered, except
for smoking cessation in pregnancy.
While this equation represents an obvious truth, it
serves to focus attention on the need to tailor intervention
strategies to different contexts. For example, in populations
where the rate of cessation attempts is low but success
rates are high, it is more efﬁcient to focus resources on
interventions to boostN. In populations whereN is already
high and S is low, it may bemore efﬁcient to seek to boost S.
Of course, N and S may affect each other. For example,
availability of more effective methods of stoppingmay boost
the rate of attempts to stop. It is necessary to consider these
issues when considering the different interventions.
Related to this is the importance of considering the
reach of an intervention. A 1 percentage-point increase
in cessation from intervention A that is delivered to
30% of smokers will have a greater population impact
than a 5 percentage-point increase from intervention B
that is accessed by only 2% of smokers. Thus, some of
the interventions being reviewed with low effectiveness
may have a greater impact than others with high
effectiveness.
This review covers all forms of tobacco use and is
intended to be applicable globally. However, as noted
earlier, almost all the evidence is from studies of smoking,
and from high-income countries.Where we have been able
to ﬁnd studies from low- and middle-income countries we
have included them. In the absence of evidence to the
contrary we propose that evidence on smoking cessation
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should be applied to all forms of tobacco cessation, and in
the absence of evidence from low- and middle-income
countries we propose that the evidence from high-income
countries be applied to all countries, interpreted in the light
of national circumstances and priorities.
In summary, this paper provides a concise review of the
evidence on tobacco cessation interventions for use in
guideline development, and in selecting and prioritizing
cessation interventions at the national level, and includes
assessments of affordability using an approach based on
the one used by the WHO. With such a diverse range of
interventions and contexts, the conclusions must be stated
in very broad terms and subject to major caveats. With this
in mind, the review is accompanied by an affordability
calculator (Supporting information) in which users can
vary their estimates to assess the impact on affordability.
METHODS
Efﬁcacy estimation
The Cochrane Library was searched to identify all
systematic reviews of the efﬁcacy of health-care tobacco
cessation interventions. Health-care interventions were
deﬁned as those that involved pharmacological treatment,
advice or support from a health-care worker, printed
materials or automated systems delivered to individuals
or groups. We have included the last two categories of
intervention, because these are important and are often
delivered by health-care agencies. We have excluded mass
media campaigns, although these can clearly promote
cessation [19]. We have also excluded electronic cigarettes
and other electronic nicotine delivery systems because of
the limited amount of available evidence in clinical settings
and variability across such products [20]. Evidence is
accumulating rapidly on these, and it is likely that we will
be able to include them in an update of this review in the
next couple of years.
Major intervention types were identiﬁed from the
reviews. Reviews relating to speciﬁc subgroups of smokers
or speciﬁc components or forms of behavioural support
(e.g. motivational interviewing, stage-based interventions,
use of incentives) were excluded in order to focus on broad
intervention categories. Those intervention types with
statistically signiﬁcant overall efﬁcacy relative to a
comparator frommeta-analyses were selected for inclusion
in this review. Supporting information, Appendix S1, shows
the reviews used for primary effect size estimation. Where
there was signiﬁcant variation (‘heterogeneity’) in effect
sizes from different studies, it was noted. Supporting
information, Appendix S2, shows Cochrane reviews that
were considered and not included or were used to qualify
judgements about effect size.
The pooled effect sizes from the meta-analyses were
recalculated as the overall percentage-point difference
between intervention and comparator conditions together
with 95% conﬁdence intervals of the estimate, taking
account of any heterogeneity in effect size across studies.
Studies included in the Cochrane reviews typically involved
6–12months of follow-up, which allows conﬁdent
extrapolation to permanent cessation in a way that can
be used for cost-effectiveness analyses [21]. Another
approach would have been to use the rate ratios (ratios of
abstinence rates in intervention versus comparison
conditions) from the published reviews and apply these to
an assumed quit rate in the control condition. The results
from this approach were very similar to those we obtained
except in the case of cytisine, where applying the rate ratio
to a common placebo quit rate resulted in higher effective
size estimates than we have used.
In the case of some interventions the target population
may be all smokers coming into contact with a clinical
service, whereas in others it may be smokers who are
willing to use a particular method to help them in a quit
attempt. Evidence from high-income countries suggests
that, even where they are widely available, only about 5%
of smokers currently use face-to-face behavioural
interventions to help them stop, but more than 30% may
use a medication such as nicotine replacement therapy,
which they can buy from a shop or pharmacy [22,23].
The key efﬁcacy statements in this review take the
following form:
• When given to [population category], [intervention
category] has been found in multiple (≥2) RCTs to
increase 6–12-month abstinence rates by [range of
values] compared with [comparator].
Effectiveness judgements
For internationally applicable statements of effectiveness, it
is important to recognize that the implementation of the
intervention, the intervention provider and population of
tobacco users may differ widely. For example, evidence on
physician advice may or may not generalize to advice from
other types of health-care worker, and the effectiveness of a
given type of health-care worker may vary across cultures.
Therefore, it is necessary to form judgements about proba-
ble transferability on the basis of inference and whatever
relevant evidence is available.
A review was conducted using PubMed and Web of
Science of studies of effectiveness of the interventions
covered by the efﬁcacy review. The initial search was
conducted using labels to identify the intervention (e.g.
‘brief advice’, ‘counselling’, ‘behavioural support’, ‘tele-
phone’, ‘nicotine replacement therapy’, ‘varenicline’,
‘bupropion’, ‘self-help’, ‘internet’, ‘text messaging’)
combined with ‘smoking cessation’ or ‘tobacco cessation’.
Studies were included if they were RCTs that could provide
information about the generalizability of the RCTs in the
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Cochrane reviews or where they were observational
studies that estimated the incremental cessation rates in
samples using the intervention, taking account of
important confounding variables such as severity of
dependence on tobacco [24]. Judgements about real-world
effectiveness were made by consensus among the authors
based on the efﬁcacy ﬁndings supplemented by this
additional information and analysis. The consensus
process involved drafting propositions and going through
an iterative process of re-drafting until all the members of
the authorship team and international advisory panel
agreed.
Affordability assessments
The starting points for affordability estimates were the
efﬁcacy estimates derived from the Cochrane reviews,
qualiﬁed if necessary by effectiveness judgements. These
were used to calculate incremental cost effectiveness ratios
for life years gained (ICERs) based on cost information (see
below). Because of the high variability in costs in different
countries, particularly in the cost of health-care worker
time, and potentially different approaches to implementa-
tion, only broad estimates could be made. However, an
affordability calculator is provided in Supporting
information, File 2 to allow users to make estimates using
their own data.
Our method of calculating ICERs [25] used life years
gained rather than quality-adjusted life years as the
outcome. This is because there is insufﬁcient information
available to assess how far quality of life (QoL) may be
affected in continuing smokers versus those who stop in
different countries, and use of quality-adjusted life years
is subject to extensive debate [26–28]. Stopping smoking
improves health-related quality of life at all ages, as well
as life expectancy, and so it would be reasonable to expect
quality-adjusted life years gained to be at least as high as
life years gained [29]. However, this also depends upon
how many of the additional life years are spent with poor
quality of life, and this is subject to too much uncertainty
for QoL to be taken into account in this review.
An effective intervention was judged to be ‘affordable’
for a given income category of country if the ICERwas less
than the per capita GDP of the reference country in that
category (Table 2 and Supporting information). The
countries chosen were Nepal, India, China and the United
Kingdom (low-, lower middle-, upper middle- and
high-income, respectively), ones with good information
on costs and close to the median per capita GDP for the
income category. We considered an intervention that
would be affordable in all four income categories to be
globally affordable. The ICER threshold of one per capita
GDP corresponds to the WHO deﬁnition of ‘highly cost
effective’. We also used the model to assess affordability in
a number of other countries representing all income
categories and regions (Supporting information).
We used World Bank data for per capita GDP expressed
in international dollars (http://data.worldbank.org/indica-
tor/NY.GDP.PCAP.PP.CD), theWHO table of costs of health-
care providers for the different WHO regions for staff costs
(http://www.who.int/choice/costs/prog_costs/en/in-
dex13.html) and expert sources for local costs of
medications for set-up and ancillary costs.
Medication costs may vary over time, with particu-
lar arrangements with manufacturers and to some de-
gree in different countries. For our model we took an
approximate average price estimate based on the infor-
mation from countries where data were available.
Where prices differ, this can be reﬂected in user input
to the model. We recommend re-computing affordabil-
ity estimates when estimates of drug costs differ from
those assumed here. This can occur when drugs come
out of patent and generic manufacturers enter the
market, or where governments purchase products at
discounted rates.
Where materials and service costs are involved (e.g. au-
tomated text messaging), we have used an upper estimate
and incorporated the set-up costs into a unit cost per quit
attempt assuming aminimum number of users. Full details
of assumptions underlying costs are given in the spread-
sheet (Supporting information) notes. Our general
principle has been to estimate costs at the upper end of a
plausible range so that affordability assessments will be
conservative.
Note that our affordability assessment takes no account
of savings in societal, individual or health-care costs
resulting from stopping tobacco use. In many countries,
these are considerable in the case of smoking and mean
that many cessation interventions produce a net ﬁnancial
beneﬁt over a given time-span.
RESULTS
The efﬁcacy, effectiveness and affordability of the major
categories of intervention are presented in this section,
with the behavioural interventions considered ﬁrst and
then the pharmacological interventions. Within each of
these categories, we consider the interventions in
approximate order in which effectiveness was ﬁrst
established by Cochrane reviews. Table 1 summarizes the
main conclusions concerning efﬁcacy while Table 2 shows
assessments of affordability.
With regard to efﬁcacy statements, some interventions
use active comparators as the control condition. For
example, face-to-face support usually uses brief advice as
a comparator which would, in itself, be expected to have
an effect. This means that the total effect of some interven-
tions will be underestimated. Therefore, Table 1 also shows
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a projected estimate of the total effect size of the interven-
tions. To be conservative, the affordability estimates use
the lower ﬁgure, but users can enter the total effect size es-
timate in the affordability calculator if they wish.
Some interventions would be expected to combine in
terms of effectiveness. For example, combining medication
to behavioural support is expected to produce an
approximately additive effect.
Behavioural interventions
Brief advice
Brief opportunistic advice involves a health-care worker
raising the topic of smoking with a patient, advising the
patient to stop and/or offering support and follow-up. It
would normally be expected to take no more than 20 -
minutes and most of the interventions evaluated took
Table 1 Efﬁcacy of health-care smoking cessation interventions from Cochrane reviews.
Intervention versus
comparison Delivered by Delivered to
Percentage point
increase in
6–12-month
abstinence
(95% CI)
Projected percentage
point increase in
6–12-month
abstinence compared
with no intervention
Brief advice from a
physician versus no intervention
Physicians Smokers attending a surgery 2 (2–3) 2
Printed self-help materials
versus nothing
Health-care provider
(e.g. health promotion
organization)
Smokers wanting help with
stopping and willing to
set a quit date
2 (1–3)a 2
Proactive telephone
support versus reactive
telephone support
Trained stop-smoking
practitioners
Smokers wanting help with
stopping and willing to
set a quit date
3 (2–4)a 5
Automated text
messaging versus
non-smoking-related messaging
Systems providers Smokers wanting help with
stopping and willing to
set a quit date
4 (3–5)a 4
Face-to-face individual
behavioural support versus
brief advice or written
materials
Trained stop-smoking
practitioners
Smokers wanting help with
stopping and willing to
set a quit date
4 (3–5)b 6
Face-to-face group-based
behavioural support versus
brief advice or written materials
Trained stop-smoking
practitioners
Smokers wanting help with
stopping and willing to
set a quit date
5 (4–7)b 7
Single NRT versus placebo Health professionalsc Smokers wanting help with
stopping and willing to
set a quit date
6 (6–7)d 6
Dual form/combination NRT
versus placebo
Health professionalsc Smokers wanting help with
stopping and willing to
set a quit date
11e 11
Cytisine versus placebo Health professionals Smokers wanting help with
stopping and willing to
set a quit date
6 (4–9)f 6
Bupropion versus placebo Health professionals Smokers wanting help with
stopping and willing to
set a quit date
7 (6–9)f 7
Nortriptyline versus placebo Health professionals Smokers wanting help with
stopping and willing to
set a quit date
10 (6–15)f 10
Varenicline versus placebo Health professionals Smokers wanting help with
stopping and willing to
set a quit date
15 (13–17)f 15
aSigniﬁcant heterogeneity. bUse of an active control may mean that the total effect size versus nothing is larger. cHealth-care worker qualiﬁed to prescribe or
provide the medication. dNo clear differences between products or interaction with intensity of behavioural support, but some evidence that higher-dose
products are more effective than lower-dose ones. eSynthetic estimate based on incremental effect of dual-form nicotine replacement therapy
(NRT) compared with single-form. fStudies were undertaken in the context of multi-session face-to-face behavioural support. CI = conﬁdence interval.
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considerably less time than this (usually approximately
5minutes).
Efﬁcacy. When given by a physician to unselected smokers
attending a consultation for a medical condition, brief
smoking cessation advice has been found in multiple RCTs
to increase 6–12-month continuous abstinence rates by an
average of 2 percentage points [95% conﬁdence interval
(CI) =2–3] compared with doing nothing or usual care,
with an advantage for more intensive compared with min-
imal advice (>20minutes) (see Table 1) [30]. Evidence for
efﬁcacy of brief opportunistic advice to stop by other health-
care workers is suggestive rather than conclusive [31,32].
There is insufﬁcient evidence to draw conclusions re-
garding the efﬁcacy of brief opportunistic health-care
worker advice to promote cessation of use of tobacco prod-
ucts other than cigarettes.
Effectiveness. Most of the RCTs thus far have been in high-
income countries with health-care systems that have near-
universal coverage, and relates only to physician advice.
There is no reason to believe that health-care worker ad-
vice would be less effective in low- and middle-income
countries. It may be more effective in populations with
minimal or no history of quitting, because the main effect
is in prompting quit attempts. A recent RCT involving
non-medical health-care workers delivering brief advice
on tobacco use cessation door-to-door in slum areas of
Delhi found an increase in 6-month biochemical veriﬁed
continuous abstinence rates of 2 percentage points (95%
CI=0.2–3) [33]. Another RCT evaluated a brief motiva-
tional intervention delivered by health-care workers in tu-
berculosis (TB) clinics in South Africa and found a doubling
of the smoking cessation rates [34]. Unfortunately, tobacco
use is very high in health-care workers in many countries
[35], and this could reduce the effectiveness of advice from
such workers. The FCTC Article 14 guidelines stress that
this issue needs addressing, with help for health-care
workers to stop [11].
Countries vary considerably in how their health-care
systems are organized, including who would deliver brief
advice and how they would be trained and motivated to
give brief advice routinely. Nevertheless, brief advice is po-
tentially usable globally with a very wide reach.
Our analysis is that brief advice to stop smoking and of-
fer of support from a health-care worker can have a small
but important effect in promoting smoking cessation in
any health-care system that invests in the necessary train-
ing and support for this activity.
Affordability. With an effect size of 2 percentage points at
6–12 months, brief advice involving an average of 20mi-
nutes of health professional time is globally affordable (see
Table 2 and Supporting information). Given that many of
the studies of brief advice have involved much less than
20minutes of advice and that we have based the costs on
physician time, the affordability is likely to be greater than
we have estimated.
Face-to-face behavioural support
Behavioural support involves advice, discussion and en-
couragement, and other activities designed to (1)maximize
motivation to remain abstinent, (2) minimize motivation to
smoke, (3) enhance the skills and capacity needed to avoid
and resist urges to smoke and (4) optimize effective use of
stop-smoking medication where available [36,37]. It can
be delivered individually or in groups. The studies con-
ducted to date have usually involved multiple sessions pro-
vided by specially trained health professionals over a period
from 1 to more than 4weeks following a target quit date.
Efﬁcacy. When given to smokers who set a quit date and
who are willing to receive such help, individual face-to-face
behavioural support has been found inmultiple RCTs to in-
crease 6–12-month continuous abstinence rates by 4
Table 2 Affordabilitya of health-care smoking cessation
interventions.
Interventionb Affordability
Low-
income
(Nepal)
Lower-
middle-
income
(India)
Upper-
middle-
income
(China)
High-
income
(UK)
Automated text
messaging
7.7 11.2 25.9 109.5
Brief health-
worker advice
2.7 7.8 18.0 12.3
Printed self-help
materials
2.4 4.6 10.8 19.3
Cytisine 1.7 4.9 11.3 15.0
Nortriptyline 1.4 4.1 9.5 8.6
Proactive
telephone
support
1.0 3.8 9.7 4.5
Face-to-face
behavioural
supportc
0.9 3.4 8.6 4.0
Bupropion 0.5 1.6 3.7 7.7
Varenicline 0.5 1.3 3.0 9.2
NRT (single)d 0.4 1.0 2.4 6.9
aAffordability is the ratio of per capita gross domestic product (GDP) to the
cost per life year gained, i.e. in order for an intervention to be affordable, the
‘additional’ cost of saving a life-yearmust be equal to or less than a country’s
per capita GDP (WHO criteria for ‘highly cost-effective’); e.g. an affordability
score of 2 means that the ‘extra’ costs required to save each life year is half of
a country’s per capita GDP (hence the intervention in question is affordable).
bAffordable interventions are marked in bold type. cOnly individual support
is included. dDual-form/combination nicotine replacement therapy (NRT)
(transdermal patch plus a faster-acting form) is more effective than single-
form, but assessing effectiveness and affordability relative to no phar-
macotherapywould require indirect comparisons and so are not included here.
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percentage points (95% CI=2–5) compared with provi-
sion of written materials or brief advice [38]. Group sup-
port has been found to increase 6–12-month continuous
abstinence rates by 5 percentage points (95% CI=4–7)
compared with printed self-help materials [39]. There is in-
sufﬁcient evidence from RCTs to draw conclusions about
whether group-based support is more effective than indi-
vidual support [39]. Behavioural support has been found
to add to the efﬁcacy of medication [40]. Behavioural sup-
port has also been found to be effective in helping smoke-
less tobacco users to quit [3].
Effectiveness. Evidence from the English stop-smoking ser-
vices, which currently treat approximately more than
500,000 smokers each year, shows success rates lower
than would be expected from the RCTevidence but greater
than would be expected from brief advice. There is consid-
erable variability between different local services and indi-
vidual practitioners [41,42]. This highlights the
importance of careful staff selection, training and assess-
ment as well as close monitoring of outcomes [43].
In the English services, group support appears to be more
effective than individual support, and specialist practitioners
(those trained and employed full-time speciﬁcally to help to-
baccousers stop) appear to bemore effective than those deliv-
ering it occasionally in addition to other clinical duties [42].
Randomized trials in Pakistan andMalaysia have found
behavioural support delivered as part of a TB screening and
treatment service to have an effect on tobacco cessation
[44,45], suggesting strongly that this kind of intervention
is practicable and effective in middle-income countries
when integrated into existing care pathways. Several stud-
ies in Arabic-speaking populations have been carried out,
with mixed results [46]. However, the quality of the studies
is low, limiting the conclusions that can be drawn.
Overall, there is reason to believe that face-to-face be-
havioural support delivered by trained health-care workers
with content developed from that used in RCTs would be ef-
fective in any health-care system. There are, however,
likely to be signiﬁcant practical and ﬁnancial barriers to
widespread implementation of programmes of this kind in
many countries, except where they can be incorporated
into existing health-care provision.
Affordability. With an effect size of 4 percentage points at
6–12months, face-to-face behavioural support involving
an average of 180minutes of health-worker time per quit
attempt would be affordable in most middle- and high-
income countries, but not in low-income countries (Table 2
and Supporting information).
Printed self-help materials
Printed self-help materials include leaﬂets, booklets and
books designed to provide encouragement, advice and
support to maximize motivation to stop smoking, reduce
motivation to smoke, enhance self-regulatory skills and ca-
pacity and, in some cases, to optimize medication use.
Efﬁcacy. When given to smokers wanting help with a quit
attempt, printed self-help materials have been found in
multiple RCTs to increase quit rates by 2 percentage points
(95%CI=1–3) comparedwith no intervention [47]. There
was signiﬁcant heterogeneity in the effect sizes.
Effectiveness. It seems reasonable to assume that self-help
materials would be effective in a wide range of contexts
and populations. It is likely that literacy would be a signif-
icant factor limiting use, given that none of the materials
evaluated relied exclusively on images. The content and
style of the materials would be expected to play an impor-
tant role in effectiveness, but there is no evidence to indi-
cate what speciﬁc components should be included.
Overall, printed self-helpmaterials would be expected to
be useful in helping smokers to stop in a wide range of
settings.
Affordability. If self-help materials could achieve an effect
size of 2 percentage points at 6–12months, they would
be globally affordable (see Table 2 and Supporting informa-
tion). If they can be distributed electronically via the inter-
net, they become even cheaper (as long as internet access
is widespread and inexpensive), as there are no printing
and distribution costs. It is also possible that in some coun-
tries many smokers would buy self-help books or booklets
themselves, so that there would be no cost to state funders.
Telephone support (quitlines)
Telephone support involves similar broad categories of ac-
tivity to face-to-face support (see above). It can be ‘proac-
tive’ or ‘reactive’. In proactive support a trained
counsellor initiates calls, following an initial enquiry by
the caller, to provide support according to an agreed sched-
ule, while in a reactive model support is available on de-
mand to people who call a quitline number.
Efﬁcacy. When given to smokers wanting help with stop-
ping, proactive telephone support has been found in multi-
ple RCTs to increase 6–12-month continuous abstinence
rates by 3 percentage points (95%CI=2–5) comparedwith
the offer of reactive telephone support only [48]. Signiﬁcant
heterogeneity exists in the effect sizes of different RCTs, with
one large study showing no effect [49]. This means that we
know that telephone support can be effective with the right
content, delivery and in the right context, but such factors
can make a substantial difference. The effect of proactive
telephone support has been found both for smokers seeking
help and those asked if they wanted support [50]. There is
insufﬁcient evidence from RCTs to draw conclusions about
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the efﬁcacy of reactive telephone support. However, as it
often includes either or both provision of self-help
materials and/or brief advice from a health professional,
it is likely to be similarly effective to them.
Effectiveness. A large pragmatic RCT of multi-lingual pro-
active telephone support versus self-help materials in Asian
smokers in California found a clear beneﬁt [51]. A recent
study in England failed to show beneﬁt from adding addi-
tional calls and the offer of free NRT to the standard proac-
tive service, although NRT is readily available to buy or on
prescription in that country and there was little difference
in usage between intervention control conditions [52].
Our analysis is that there is good reason to believe that
proactive telephone support can aid smoking cessation in
any country, although it would be important to monitor
success rates to establish that a speciﬁc service was deliver-
ing expected results.
Affordability. With an effect size of 3 percentage points at
6–12months over reactive support and an average of
120minutes of contact time per quit attempt, telephone
support would be globally affordable (see Table 2 and
Supporting information).
Automated text messaging
Automated text messaging aims to deliver content similar
to face-to-face behavioural support, focusing on motiva-
tional messages, advice on coping with cravings and pro-
viding behavioural distraction when needed [53].
Efﬁcacy. When given to smokers wanting help with stop-
ping, automated text messaging interventions have been
found in multiple RCTs to increase 6–12-month continu-
ous abstinence rates by 4 percentage points (95% CI=3–
5) compared with text messaging programmes providing
generic health advice [54]. There is signiﬁcant heterogene-
ity in the effect sizes of the studies.
Effectiveness. As long as the content of programmes on of-
fer to smokers is based on what was in the successful RCTs,
there is reason to believe that broadly similar effects to
those found in the RCTs would be seen. A large trial of a
text messaging intervention, Text2Stop, showed a clear
beneﬁt [55], and an analysis of the content of this interven-
tion has been published [56] which could form a basis for
development of other programmes.
Our analysis is that automated text messaging
programmes can support smokers to stop and the content
of the programmes should be based on those that have
shown a clear beneﬁt.
Affordability. With an effect size of 4 percentage points at
6–12months, automated text messaging is globally
affordable (see Table 2 and Supporting information), and
could potentially have very good reach, as some low- and
middle-income countries have high mobile phone
ownership. Affordability will vary for governments as a
function of who bears the phone costs, the government
or the individual, but even if text messaging were entirely
government-funded it is still likely to be one of the most af-
fordable of all interventions.
Pharmacological interventions
NRT. NRT consists of products designed to deliver nicotine
into the body in a form that does not involve smoking or
ingestion of other toxins. The forms currently licensed for
use in at least some countries of the world are 16- or
24-hour transdermal patches, 2- or 4-mg chewing gum,
1-, 1.5-, 2- or 4-mg nicotine lozenges, 2-mg sublingual
tablet, nasal spray, inhalator, buccal pouch and mouth
spray. Other nicotine products (e.g. some types of
electronic nicotine delivery devices) are likely to be added
to this list of licensed medicines in the coming years.
Smokers typically use these products startingon the designed
target quit day and continuing for up to 12weeks. Use can
be started before the quit date, and they can be used for
smoking reduction with a view to quitting at a later date.
Efﬁcacy. When given to smokers of 15 or more cigarettes
per day who are making a quit attempt on a pre-speciﬁed
day and willing to use NRT, multiple RCTs have shown that
this type of aid increases 6–12-month continuous absti-
nence rates by 6 percentage points (95% CI=6–7) com-
pared with placebo [57]. These studies all involved some
degree of contact with a health professional. There is no ev-
idence from RCTs that the amount of health professional
contact makes a difference to the effectiveness of the NRT
although, as noted above, behavioural support has been
shown to have an additive effect in and of itself [40].
There is insufﬁcient information to draw conclusions
about whether one form of NRT is likely to be more effec-
tive than another, overall, but evidence suggests that
higher-dose forms may be more effective than lower-
dose forms [57].
Evidence from multiple RCTs has shown that combin-
ing a nicotine patch with a faster-delivery form of NRT
(such as gum) increases 6–12-month abstinence rates by
5 percentage points compared with single-form NRT
(95% CI=3–7) [57].
NRT has not been adequately evaluated in smokers of
fewer than 10 cigarettes per day and most studies have in-
volved smokers of 15 or more cigarettes per day.
There is insufﬁcient evidence from RCTs to draw ﬁrm
conclusions as to whether or not NRT is an effective aid
for smokeless tobacco cessation [58].
Effectiveness. Several cross-sectional surveys have been re-
ported as having failed to ﬁnd that smokers using NRT to
aid a quit attempt are more likely to still be abstinent at
the time of the survey [59–61], but the data have, in some
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cases, been misinterpreted. Importantly, they failed to ad-
just adequately for major confounding variables such as
dependence, and it is known that more dependent smokers
opt to use NRT [62,63]. A large cross-sectional study and a
prospective study that adjusted for nicotine dependence
found an effect of NRT when prescribed or given by a
health professional that was similar to that found in RCTs,
but no effect when NRT was bought over the counter
[64,65]. Two other adequately designed prospective stud-
ies with sufﬁcient power to detect an effect of NRT found
that, adjusting for major confounding factors, smokers
who used NRT in their most recent quit attempt weremore
likely than those who did not to maintain abstinence
[66,67]. Both were multi-national cohort studies. One in-
volved follow-up for 6months and the other for a year;
the effect size in both cases was in line with what would
be predicted from the RCTs. It has also been shown that
smokers in the English stop-smoking services who use
NRTaremore likely to succeed in the short term than those
who elect not to use anymedication [41]. A note of caution
is sounded by the fact that the only RCTof nicotine patches
in a low-income country failed to ﬁnd an effect [68].
Overall, our analysis suggests that NRT in the context of
at least some behavioural support can aid smoking cessa-
tion in moderately heavy or heavy smokers. It appears
not to be effective when bought from shops with no behav-
ioural support. Combining transdermal patches with a
faster-acting product such as chewing gum or lozenge is
more effective than using either alone.
Affordability. With an effect size of 6 percentage points at
6–12months, and assuming up to 40minutes of health-
worker time to explain and supervise use, NRT is affordable
in middle- and high-income countries but not in low-
income countries (see Table 2 and Supporting informa-
tion). Generic NRT can now be produced cheaply, and this
will increase its affordability. Prescribing combination NRT
(patch plus a faster-acting form) is likely to be more cost-
effective because of the additional effectiveness of the med-
ication without an increase in prescriber time for supervi-
sion (see Supporting information).
Bupropion/amfebutamone (sustained release)
Bupropion hydrochloride is an atypical antidepressant that
has multiple actions in the brain involving dopamine and
noradrenaline pathways andmayalso act as a nicotinic an-
tagonist. A typical course is 300mg per day for 7–8weeks,
beginning a week prior to the designated quit date.
Efﬁcacy. When used by smokers of 15 or more cigarettes
per day, multiple RCTs have shown that this medication
increases 6–12-month continuous abstinence rates by
7 percentage points (95% CI = 6–9) compared with
placebo [69].
There is insufﬁcient evidence from RCTs to draw con-
clusions about whether 300mg (the standard dose) is
more effective than 150mg [69].
Extending the course of treatment beyond 8weeks ap-
pears to increase abstinence rates while the medication is
being taken, but not when assessed 12months after the
medication has been discontinued [69].
Bupropion has not been shown to be effective for
treating users of smokeless tobacco [3].
Evidence suggests that bupropion is broadly similar in
effectiveness to NRT [69].
Effectiveness. Bupropion has not been tested without be-
havioural support. Smokers who use it in the English
stop-smoking services have similar short-term success
rates to those who use single-form NRT and higher than
those who use no medication [41]. An RCT undertaken
in English clinical services found bupropion and the combi-
nation of bupropion and NRT to produce similar 6-month
continuous abstinence rates to single-form NRT [70]. A
prospective multi-national population-level study also
found that, after adjusting for potential confounding vari-
ables, smokers who used bupropion in a quit attempt were
more likely than those who did not to succeed in stopping
[67]. A note of caution is sounded by the failure of the only
RCTof bupropion in a non-high-income country to show a
beneﬁt, although treatment groups were not equivalent
and smokers had suspected tuberculosis, so further trials
are needed [44].
Our analysis is that bupropion is a useful aid to smoking
cessation inmoderately heavy or heavy smokers, at least in
the context of behavioural support, and is at least as effec-
tive as single-form NRT.
Affordability. With an effect size of 7 percentage points at
6–12months, bupropion, together with approximately
60minutes of health professional time for screening and
checking of adverse reactions, is affordable in middle- and
high-income countries but not in low-income countries
(see Table 2 and Supporting information). One hour of phy-
sician time has been speciﬁed for supporting medication
use because the safety proﬁle and contraindications of
bupropion mean that a prescriber would need to spend
some time addressing these.
Nortriptyline
Nortriptyline is a tricyclic antidepressant. For smoking ces-
sation the dose is typically 75–100mg per day for
12–14weeks, starting 1week before the quit date. Because
of the side-effect proﬁle, it needs close supervision to mon-
itor and possibly adjust the dose.
Efﬁcacy. When used by smokers of 15 or more cigarettes
per day nortriptyline has been found inmultiple RCTs to in-
crease 6-month continuous abstinence rates by 10 (95%
CI=6–15) percentage points compared with placebo
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[69]. Minor adverse events are common, particularly dry
mouth, but these rarely cause discontinuation of
treatment.
Effectiveness. Nortriptyline has not been evaluated with-
out behavioural support. There is a reasonable presump-
tion that similar tricyclic antidepressants such as
amitriptyline are also effective, but these have not been
tested directly.
A randomized trial among prisoners in Australia did
not ﬁnd a beneﬁt from nortriptyline over and above behav-
ioural support [71]. An observational study in Brazil found
smokers who used nortriptyline achieved abstinence rates
at least as high as those using bupropion or NRT [72]. A
randomized trial in the United Kingdom found no beneﬁt
to adding nortriptyline to NRT [73].
Our assessment is that nortriptyline in moderately
heavy or heavy smokers in the context of behavioural sup-
port aids smoking cessation. Patients using it experience
some minor adverse reactions, particularly dry mouth,
but these are not sufﬁcient to undermine effectiveness.
Affordability. Nortriptyline is inexpensive, although the
side-effect proﬁle of the drug requires more extensive super-
vision. With an effect size of 10 percentage points at
6–12months, assuming 120minutes of prescriber time
for supervision, nortriptyline is affordable globally (see Ta-
ble 2 and Supporting information).
Varenicline
Varenicline is a partial agonist designed to bind with
high afﬁnity to the nicotinic acetylcholine receptor
composed of alpha-4 beta-2 subunits [74]. A standard
course of treatment is 1mg per day beginning 1week
before the designated quit [74], then 11weeks at
2mg per day. Minor side effects reported are nausea
and sleep disturbance. These do not appear to lead to
signiﬁcant treatment discontinuation. Reports during
post-marketing surveillance of raised risk of serious
neuropsychiatric and cardiac adverse events have not
been conﬁrmed by controlled studies [75–78].
Efﬁcacy. When used by smokers of 15 or more cigarettes
per day, multiple RCTs have shown that this medication in-
creases 6–12-month continuous or sustained abstinence
rates by 15 percentage points (95% CI=13–17) compared
with placebo and 7 percentage points (95% CI=4–11)
compared with bupropion [74].
Evidence from RCTs suggests that varenicline is more
effective than nicotine patches [74].
One trial has shown varenicline to help people stop
using smokeless tobacco [3].
Effectiveness. Varenicline has not been evaluated in RCTs
without what would be considered intensive behavioural
support (multiple sessions with at least 120minutes of to-
tal contact time), but an international cohort study
strongly suggested effectiveness in routine clinical practice
[67]. Evidence from the English stop-smoking services sup-
ports ﬁndings from RCTs that varenicline is more effective
than bupropion or single-form NRT [41].
Our assessment is that varenicline in moderately heavy
or heavy smokers in the context of behavioural support
aids smoking cessation. On average, it is more effective
than bupropion and single-form NRT and at least as effec-
tive as combination NRT. Although there is little reason
at present to believe that it can cause serious side effects,
concerns have been raised and it has been suggested that
health-care workers show particular vigilance in case
these emerge.
Affordability. With an effect size of 15 percentage points at
6–12months varenicline, together with approximately
60minutes of health professional time, is affordable in
middle- and high-income countries, but not in low-income
countries (see Table 2 and Supporting information).
Cytisine
Cytisine is a partial agonist binding with high afﬁnity to the
nicotinic acetylcholine receptor composed of alpha-4 beta-
2 subunits [74]. A standard course of treatment is 4weeks,
beginning 1week before the designated quit date, with a
dosing regimen that reduces over time. It was the ﬁrst med-
ication ever to be licensed as a smoking cessation aid, and
has been in use in eastern Europe for more than 40years.
In Russia and Poland it is available for purchase over the
counter. No serious side effects have been detected. Nausea
is a common minor side effect but does not lead to signiﬁ-
cant discontinuation of treatment.
Efﬁcacy. When used by smokers of 15 ormore cigarettes per
day, cytisine has been found in multiple RCTs to increase 6–
12-month continuous abstinence rates by 6 percentage
points (95% CI=4–9) compared with placebo [74].
Effectiveness. An observational study from a large clinic in
Warsaw found 12-month biochemically veriﬁed absti-
nence rates somewhat greater than was found in a large
clinical trial in the same clinic [79,80]. This suggests that
the results of the RCTs would translate into at least as high
success rates in routine clinical practice.
An open-label RCT in smokers calling the New Zealand
telephone helpline found cytisine to be more effective than
nicotine replacement therapy [81].
There are more than 4 million users on the Euro-
pean Medicines Agency drug safety database, and no
evidence has emerged of any safety problems, suggest-
ing that this drug has a benign safety proﬁle and is
suitable for purchase with minimal or no medical su-
pervision, as is currently the case in Russia and
Poland.
Our assessment is that cytisine is an effective aid to ces-
sation in moderately heavy to heavy smokers.
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Affordability. With an effect size of 6 percentage points at
6–12months, and requiring relatively little clinical super-
vision (approximately 40minutes), cytisine would be glob-
ally affordable (see Table 2 and Supporting information).
DISCUSSION
Table 3 gives a narrative summary of the judged effective-
ness and affordability of the interventions reviewed. All
are judged to be affordable in middle- and high-income
countries and many are affordable in low-income
countries.
The most effective combination of interventions on the
basis of our review is face-to-face behavioural support
together with combination NRT or varenicline. How-
ever, this combination is currently only likely to be
affordable in middle- and high-income countries
(although, of course, users who can afford it may choose
to pay for it).
A major outcome of this review is that, based on
reasonable assumptions about cost, and not taking any
account of cost savings from tobacco cessation, health-
care systems of countries in every World Bank income
category should be able to afford to implement smoking
cessation interventions of established efﬁcacy. Most
Table 3 Narrative summary of main conclusions.
Intervention Effectiveness Affordability
Brief opportunistic advice
from a health-care worker
This is an effective means of promoting tobacco cessation.
The main issue is likely to be motivating and training
health workers to deliver this intervention routinely as
well as ensuring that the health-care worker is not a
tobacco user. It may be that offering help with stopping
to all tobacco users provides optimum results
Globally affordable
Printed self-help materials This is an effective means of promoting tobacco cessation.
It will be important to match intervention content as
closely as possible to what has been found to be effective
Globally affordable
Proactive telephone support This is an effective means of promoting tobacco cessation.
Effectiveness will depend upon having in place appropriate
procedures for selection, training, assessment and
professional development of practitioners as well as
evidence-based treatment protocols
Globally affordable
Automated text messaging This is an effective means of promoting tobacco cessation.
It will be important to match intervention content as
closely as possible to what has been found to be effective
Globally affordable
Face-to-face behavioural support This is an effective means of promoting tobacco cessation.
In many countries it may need to be integrated into
existing services (e.g. tuberculosis screening). Effectiveness
will depend upon having in place appropriate procedures
for selection, training, assessment and professional
development of practitioners as well as evidence-based
treatment protocols. Its effect appears to be broadly
additive to medication if that is being used
Affordable in middle- and
high-income countries
Nicotine replacement therapy This is an effective intervention when provided by a health-
care worker. Best results can be achieved by combining a
transdermal patch with a faster-acting form
Affordable in middle- and
high-income countries
Cytisine This is an effective intervention when provided by a health-
care worker
Globally affordable
Bupropion This is an effective intervention when provided by a health-
care worker. It is broadly similar in effectiveness to single-
form NRT
Affordable in middle- and
high-income countries
Nortriptyline This is an effective intervention when provided by a
health-care worker
Globally affordable
Varenicline This is an effective intervention when provided by a
health-care worker. It is more effective than bupropion and
single-form NRT
Affordable in middle- and
high-income countries
NRT = nicotine replacement therapy.
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notably, these are brief advice from a health-care worker,
proactive telephone support, printed self-help materials,
text messaging support and provision of medication
such as cytisine or nortriptyline. Clearly, there are major
practical challenges to achieving this and countries not
currently doing this will need to give careful consider-
ation to the pace of development that can be achieved,
and which interventions to prioritize. Nevertheless, this
review and our affordability calculator offer a basis for
countries to establish what level of cessation provision
they might aim for.
It is important to note that the affordability judgements
are very broad, and do not take into account important fac-
tors that may be operating in particular countries. For ex-
ample, in countries such as Brazil and India, income is
highly skewed and there are large numbers of very poor
people in rural communities with limited access to health
care. Furthermore, in many countries health care is pro-
vided principally by health-care workers who are not med-
ically or professionally trained, and in others by traditional
health practitioners. This may necessitate considerable ad-
aptation of training in, for example, brief advice, to local
culture, infrastructure and traditions. A recent interna-
tional survey of treatment provision found broad agree-
ment with our ﬁndings of the affordability of medications
globally [13].
This review has identiﬁed many important gaps in the
tobacco cessation literature. There is little evidence about
interventions relating to tobacco use other than cigarette
smoking. More evidence is needed on how to deliver effec-
tive behavioural support, both in terms of the development
of treatment manuals and delivery by individual practi-
tioners. It is also important to identify factors that inﬂuence
medication effectiveness in real-world settings, including
adherence to the treatment regimen, to assess the potential
for internet-based interventions and how to make inter-
ventions more attractive to tobacco users. There are now
more than 250 smartphone applications that claim to aid
smoking cessation, but these have not yet been evaluated
adequately [82]. Research is also needed to investigate
how to implement brief advice in primary and secondary
health-care in high- as well as middle- and low-income
countries. Research is needed into the potential for elec-
tronic nicotine delivery systems and inmethods to improve
the reach and/or effectiveness of nicotine replacement
therapies. A key priority is how best to motivate and sup-
port practitioners and adapt health-care delivery systems
to integrate brief advice into health-care systems, as rec-
ommended by the FCTC Article 14 guidelines.
There is a signiﬁcant gap in the literature on the effec-
tiveness of combining different interventions.We have used
an additive model for the combination of behavioural sup-
port and medication, but it is not clear whether this is cor-
rect. It could have been anything from multiplicative to
partially additive. This is an important area for future
research.
Our current understanding of affordability of tobacco
cessation interventions could beneﬁt hugely from more
advanced economic modelling when better data become
available. Until such time, we believe that our custom-
izable spreadsheet will provide local decision-makers
with a practical, evidence-based tool to help select effec-
tive, affordable tobacco cessation interventions for their
country.
This review has not considered tobacco harm reduc-
tion, deﬁned as ‘measures taken to reduce the harm from
continued use of tobacco or tobacco-derived products’.
This typically involves users reducing consumption of ciga-
rettes or switching to less harmful products. For example,
the smokeless tobacco, snus, may provide a means of stop-
ping smoking.
A crucial issue with regard to effectiveness, affordability
and reach concerns the logistics of delivering interventions
and the effects of the setting on these parameters. This will
vary considerably across countries and regions, and it is
likely that considerable local expertise will be required to
establish how interventions can be integrated with existing
services.
This review has been produced to support country-
speciﬁc national guideline development for smoking cessa-
tion by serving as a review of the evidence base, thus re-
moving the need for a country to re-review the evidence,
a process that can be costly and time-consuming, and to
provide a starting point for considering what resources to
devote to tobacco cessation support, and what the opti-
mum blend of interventions might be. We hope it will be
used alongside a detailed analysis at country level, by all
relevant stakeholders working together, to determine ces-
sation priorities within a country.
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